SCHEMBL12377801

SCHEMBL12377801

Cc1cccc(-c2nnc(NC(C)C)o2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.59
HPGD P15428 5/20 0.59
NPC1 O15118 5/20 0.59
RAB9A P51151 5/20 0.59
TSHR P16473 2/20 0.59
TP53 P04637 4/20 0.54
ALDH1A1 P00352 2/20 0.54
POLB P06746 1/20 0.54
HSD17B10 Q99714 1/20 0.54
LMNA P02545 3/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MAPK1 P28482 2/20 0.53
OPRK1 P41145 1/20 0.53
HTT P42858 1/20 0.53
CCR6 P51684 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
KDM4E B2RXH2 5/20 0.49
CA1 P00915 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11674120 0.80 SMN1; SMN2 (0.89) SMN1; SMN2HPGDNPC1RAB9ATSHR
SCHEMBL12377800 0.79 KDM4E (0.68) SMN1; SMN2HPGDNPC1RAB9ATSHR
SCHEMBL13882293 0.78 SMN1; SMN2 (0.85) SMN1; SMN2HPGDNPC1RAB9ATSHR
SCHEMBL28615565 0.78 GSK3B (0.71) SMN1; SMN2HPGDNPC1RAB9ATSHR
SCHEMBL16675211 0.77 SMN1; SMN2 (0.82) SMN1; SMN2HPGDNPC1RAB9ATSHR
SCHEMBL12974 0.75 HPGD (0.73) SMN1; SMN2HPGDNPC1RAB9ATSHR
SCHEMBL27775495 0.75 GSK3B (0.40) SMN1; SMN2NPC1RAB9ATP53MEN1
SCHEMBL97607 0.74 HPGD (0.61) SMN1; SMN2HPGDNPC1RAB9ATSHR
SCHEMBL97608 0.74 HPGD (0.61) SMN1; SMN2HPGDNPC1RAB9ATSHR
SCHEMBL12634931 0.74 NPC1 (0.83) SMN1; SMN2HPGDNPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KCNJ1, KCNJ11, ADRA1D SMN1; SMN2 3525/4885HPGD 864/4885NPC1 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.